RNA-Seq of isogenic human iPS cell-derived cardiomyocytes with RBM20 mutations created by CRISPR/Cas9

RBM20 homozygous point mutation (P633L and R634Q), as well as homozygous frameshift deletion (S635FS) were created by CRISPR/Cas9 in an iPS cell line generated from a healthy individual. One clone that underwent the genome editing procedure without gaining a mutation in the RBM20 gene was selected and used as wild-type (WT) control, together with its parental control (WT-NC). All the iPSC lines were differentiated into iPSC-CMs via modulation of WNT signaling, selected via glucose starvation, and then matured for 4 more weeks before each experiment.